BioArctic AB (publ) (BRCTF)
USD 15.67
(0.0%)
USD 15.67
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 139.5 Million SEK | 93.58% |
| 2022 | 72.06 Million SEK | -33.92% |
| 2021 | 109.05 Million SEK | -23.75% |
| 2020 | 143.01 Million SEK | -31.52% |
| 2019 | 208.83 Million SEK | -44.36% |
| 2018 | 375.3 Million SEK | -25.59% |
| 2017 | 504.34 Million SEK | -22.07% |
| 2016 | 647.21 Million SEK | 2735.43% |
| 2015 | 22.82 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 202.61 Million SEK | 41.09% |
| 2024 Q1 | 143.6 Million SEK | 2.94% |
| 2023 Q3 | 113.52 Million SEK | 22.65% |
| 2023 Q1 | 69.56 Million SEK | -3.48% |
| 2023 FY | 139.5 Million SEK | 93.58% |
| 2023 Q2 | 92.55 Million SEK | 33.06% |
| 2023 Q4 | 139.5 Million SEK | 22.88% |
| 2022 Q1 | 101.67 Million SEK | -6.77% |
| 2022 Q4 | 72.06 Million SEK | 5.7% |
| 2022 Q2 | 94.63 Million SEK | -6.92% |
| 2022 FY | 72.06 Million SEK | -33.92% |
| 2022 Q3 | 68.17 Million SEK | -27.96% |
| 2021 FY | 109.05 Million SEK | -23.75% |
| 2021 Q4 | 109.05 Million SEK | -14.83% |
| 2021 Q3 | 128.03 Million SEK | -0.87% |
| 2021 Q2 | 129.16 Million SEK | 1.37% |
| 2021 Q1 | 127.42 Million SEK | -10.9% |
| 2020 Q2 | 159.38 Million SEK | -2.93% |
| 2020 Q3 | 155.93 Million SEK | -2.16% |
| 2020 Q4 | 143.01 Million SEK | -8.29% |
| 2020 FY | 143.01 Million SEK | -31.52% |
| 2020 Q1 | 164.18 Million SEK | -21.38% |
| 2019 Q4 | 208.83 Million SEK | -15.9% |
| 2019 Q2 | 275.72 Million SEK | -2.59% |
| 2019 Q1 | 283.07 Million SEK | -24.58% |
| 2019 Q3 | 248.33 Million SEK | -9.94% |
| 2019 FY | 208.83 Million SEK | -44.36% |
| 2018 FY | 375.3 Million SEK | -25.59% |
| 2018 Q4 | 375.3 Million SEK | 7.31% |
| 2018 Q2 | 407.05 Million SEK | -10.95% |
| 2018 Q1 | 457.11 Million SEK | -9.37% |
| 2018 Q3 | 349.73 Million SEK | -14.08% |
| 2017 FY | 504.34 Million SEK | -22.07% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 Q2 | 574.6 Million SEK | 0.0% |
| 2017 Q3 | 546.84 Million SEK | -4.83% |
| 2017 Q4 | 504.34 Million SEK | -7.77% |
| 2016 FY | 647.21 Million SEK | 2735.43% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | 647.21 Million SEK | 0.0% |
| 2015 FY | 22.82 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -161.707% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -1355.883% |
| SQZ Biotechnologies Company | 50.03 Million USD | -178.789% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -92.495% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -136.389% |
| Mesoblast Limited | 188.44 Million USD | 25.971% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -3522.115% |
| Genus plc | 485 Million USD | 71.236% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -2287.678% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -5443.912% |
| Marizyme, Inc. | 26.67 Million USD | -422.959% |
| ContraFect Corporation | 32.53 Million USD | -328.831% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -3571.132% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -6940.955% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -3544.614% |
| Intellipharmaceutics International Inc. | 12 Million USD | -1061.676% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -1084.417% |
| MultiCell Technologies, Inc. | 1617.67 USD | -8623599.518% |
| Accustem Sciences Inc. | 1.07 Million USD | -12826.053% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -80.197% |
| EV Biologics, Inc. | 2.11 Million USD | -6495.671% |
| Q BioMed Inc. | 8.13 Million USD | -1615.284% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -68.208% |
| Neon Bloom, Inc. | 1.22 Million USD | -11276.735% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -2610.883% |
| Biomind Labs Inc. | 1.49 Million USD | -9208.814% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 42.844% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -658.028% |
| Skye Bioscience, Inc. | 14.07 Million USD | -891.335% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -6839.999% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -98075.868% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -1373.739% |
| IMV Inc. | 37.93 Million USD | -267.764% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -69264.446% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -2327.904% |
| GB Sciences, Inc. | 5.41 Million USD | -2475.017% |
| Alpha Cognition Inc. | 7.16 Million USD | -1847.068% |
| HST Global, Inc. | 593.59 Thousand USD | -23401.456% |
| CSL Limited | 18.62 Billion USD | 99.251% |
| Halberd Corporation | 728.71 Thousand USD | -19043.593% |
| Enzolytics Inc. | 365.26 Million USD | 61.808% |
| Resverlogix Corp. | 67.39 Million USD | -106.99% |
| Affymax, Inc. | 8.87 Million USD | -1472.574% |
| SYBLEU INC | 681.41 Thousand USD | -20372.606% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -16532.607% |
| argenx SE | 444.95 Million USD | 68.648% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -86.203% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -8039.032% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -1071.989% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -3706.187% |
| AVAX Technologies, Inc. | 3.99 Million USD | -3393.037% |
| Zenith Capital Corp. | 27.56 Thousand USD | -505914.001% |
| Genscript Biotech Corporation | 1.32 Billion USD | 89.478% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -58354.08% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -3635.714% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -20390.017% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -17.504% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -1442.8% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -208334.311% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -9629.186% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -177.541% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -5044.597% |
| BioStem Technologies, Inc. | 15.9 Million USD | -777.12% |
| ONE Bio Corp. | 27.49 Million USD | -407.361% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -29920.078% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -508422.582% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -10978.762% |
| Agentix Corp. | 2.51 Million USD | -5456.66% |
| LadRx Corporation | 2.2 Million USD | -6239.524% |
| Cell Source, Inc. | 15.8 Million USD | -782.555% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -312015.178% |
| Regen BioPharma, Inc. | 5.45 Million USD | -2456.116% |
| Regen BioPharma, Inc. | 5.45 Million USD | -2456.116% |
| NovAccess Global Inc. | 7.86 Million USD | -1674.682% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -463.739% |
| Itoco Inc. | 1.65 Million USD | -8338.612% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -6699.833% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -2206.216% |
| Kadimastem Ltd | 3.5 Million USD | -3880.265% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -32991.459% |
| CytoDyn Inc. | 127.89 Million USD | -9.077% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -333647.219% |
| Mobile Lads Corp. | 1.31 Million USD | -10520.732% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -8806.093% |
| Qrons Inc. | 1.48 Million USD | -9270.711% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -1163.009% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -17148.273% |
| Rebus Holdings, Inc. | 5.24 Million USD | -2561.255% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -2186.22% |
| International Stem Cell Corporation | 5.27 Million USD | -2543.604% |
| Bioxytran, Inc. | 3.24 Million USD | -4193.06% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -22191.626% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -2921.426% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -240.284% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -526.557% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -6787.721% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -2446.605% |
| Neutra Corp. | 973.52 Thousand USD | -14229.619% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -380.796% |
| PureTech Health plc | 125.58 Million USD | -11.084% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -3613.025% |
| IXICO plc | 1.9 Million USD | -7241.135% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -579.541% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -35.015% |
| CSL Limited | 18.62 Billion USD | 99.251% |
| Cellectis S.A. | 249.36 Million USD | 44.058% |